Securities Litigation (removed) — Securities class action and derivative suits previously disclosed over manufacturing contamination allegations are no longer mentioned, with no update on case status, settlement terms, or financial impact.

NASDAQ: SCYX SCYNEXIS INC 10-Q

SCYNEXIS pivots to rare kidney disease, acquires SCY-770 for $8M upfront, raises $40M

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 15, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade SCYX commission-free

Open an account, get a free stock.

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 1, 2026 7:09 PM